CUE - Cue Biopharma, Inc.
| Previous Close | 7.43 |
| Open | 7.36 |
| Bid | 7.55 x 800 |
| Ask | 8.90 x 1300 |
| Day's Range | 7.36 - 7.85 |
| 52 Week Range | 4.16 - 12.00 |
| Volume | 339,150 |
| Avg. Volume | 82,893 |
| Market Cap | 156.913M |
| Beta (3Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.11 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 14.50 |
- Simply Wall St.•9 days ago
Do Insiders Own Shares In Cue Biopharma, Inc. (NASDAQ:CUE)?
The big shareholder groups in Cue Biopharma, Inc. (NASDAQ:CUE) have power over the company. Generally speaking, as a...
- GlobeNewswire•2 months ago
Cue Biopharma to Present Corporate Overview & Clinical Strategy for CUE-101 at Jefferies 2019 Healthcare Conference
Cue Biopharma, Inc., (CUE) an innovative clinical stage immunotherapy company developing a novel, proprietary class of biologics engineered to selectively modulate the human immune system to treat cancer, autoimmune and chronic infectious diseases, announced today it will present a corporate overview and update at the Jefferies 2019 Healthcare Conference on Thursday, June 6, 2019 at 3:00 pm ET in New York City. Daniel Passeri, M.Sc., J.D., President and Chief Executive Officer, will provide an overview of the translational-based clinical strategy for the Company’s lead program CUE-101, that recently received IND acceptance from the FDA. The presentation will also be archived for 30 days on the Investors section of the Company's website at www.cuebio.com.
- GlobeNewswire•2 months ago
Cue Biopharma to Host Business Update Call and Webcast
Cue Biopharma, Inc., (CUE) an innovative immunotherapy company developing a novel, proprietary class of biologics engineered to selectively modulate the human immune system to treat cancer, autoimmune and chronic infectious diseases, announced today it will host a conference call and webcast to provide a business update on May 21, 2019 at 4:30 pm ET. Live and archived versions of the event can be accessed via the Company’s website. Members of the Cue Biopharma executive management team will provide an update on the Company’s platform and pipeline progress, as well as updates on its strategic objectives and anticipated milestones.
- GlobeNewswire•2 months ago
Cue Biopharma Announces FDA Acceptance of IND for Lead Immuno-oncology Candidate, CUE-101, in Treatment of HPV-driven Cancers
Cue Biopharma, Inc., (CUE), an innovative clinical stage immunotherapy company, developing a novel, proprietary class of biologics engineered to selectively modulate the human immune system to treat cancer, autoimmune and chronic infectious diseases, announced today the U.S. Food and Drug Administration (FDA) has accepted the Company’s Investigational New Drug (IND) application for its lead immuno-oncology candidate, CUE-101, an Immuno-STAT™ (Selective Targeting and Alteration of T cells) biologic, as a potential treatment for HPV-associated cancers. “FDA acceptance of our IND filing for CUE-101 is an important step toward validating our approach for selective modulation of disease-relevant T cells directly in patients with an “off-the shelf” biologic.
- GlobeNewswire•2 months ago
Dr. Anish Suri, Cue Biopharma’s CSO, to Participate in Panel Discussion at Upcoming NYAS Frontiers in Cancer Immunotherapy Conference
Cue Biopharma, Inc., (CUE) an innovative immunotherapy company developing a novel, proprietary class of biologics engineered to selectively modulate the human immune system to treat cancer, autoimmune and chronic infectious diseases, announced today Anish Suri, Ph.D., Senior Vice President and Chief Scientific Officer will participate in a panel discussion entitled “Novel Approaches from Biotech,” Session 4, Breakout Track A, at The New York Academy of Sciences (NYAS), Frontiers in Cancer Immunotherapy Conference on Wednesday, May 15 at 1:00 PM ET in New York. Dr. Suri will discuss the Immuno-STAT™ (Selective Targeting and Alteration of T cells) platform, including mechanistic data demonstrating the specificity and selectivity of the Immuno-STAT biologics framework and its ability to target tumor-specific T cells and activate them into potent cytotoxic killer T cells.
- Simply Wall St.•3 months ago
If You Had Bought Cue Biopharma (NASDAQ:CUE) Stock A Year Ago, You'd Be Sitting On A 25% Loss, Today
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! It is doubtless a positive to see that the Cue Biopharma, Inc. (NASDAQ:CUE) share price has gained...
- GlobeNewswire•3 months ago
Cue Biopharma to Present Immuno-STAT Platform Technology at PEGs Boston 2019
CAMBRIDGE, Mass., April 08, 2019 -- Cue Biopharma, Inc. (NASDAQ: CUE), an innovative immunotherapy company developing a novel, proprietary class of biologics engineered to.
- GlobeNewswire•4 months ago
Cue Biopharma to Present Corporate Overview and Update at the Oppenheimer 29th Annual Healthcare Conference
Cue Biopharma, Inc., (CUE) an innovative immunotherapy company developing a novel, proprietary class of biologics engineered to selectively modulate the human immune system to treat cancer, autoimmune and chronic infectious diseases, announced today that it will present a corporate overview at the Oppenheimer 29th Annual Healthcare Conference on Tuesday, March 19, 2019 at 10:20 am ET, at the Westin New York Grand Central in New York City. Daniel Passeri, M.Sc., J.D., President and Chief Executive Officer, will provide an update on the Company’s Immuno-STAT™ platform and pipeline progress for the Cue-100 series.
- GlobeNewswire•5 months ago
Cue Biopharma to Present Corporate Update at 2019 BIO CEO & Investor Conference
Cue Biopharma, Inc., (CUE) an innovative immunotherapy company developing a novel, proprietary class of biologics engineered to selectively modulate the human immune system to treat cancer, autoimmune and chronic infectious diseases, announced today that it will be presenting an update at the BIO CEO & Investor Conference on Tuesday, February 12, 2019, at 10:00 am ET (Hudson/Empire Room), at the New York Marriott Marquis Hotel, NY. Daniel Passeri, M.Sc., J.D., President and Chief Executive Officer, will provide an overview of the Company's Immuno-STAT™ platform and development strategy as well as pre-clinical data updates on key programs and anticipated milestones. This design enables Immuno-STAT Biologics to engage with the T cell population of interest, resulting in highly targeted T cell modulation.
- Simply Wall St.•6 months ago
Cue Biopharma, Inc. (NASDAQ:CUE) Insiders Increased Their Holdings
We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. The flip side of that is that there are more Read More...
- GlobeNewswire•6 months ago
Cue Biopharma Announces Presentation Highlighting Immuno-STAT Platform and CUE-101 at the 2019 Keystone Symposia Conference
CAMBRIDGE, Mass., Jan. 16, 2019 -- Cue Biopharma, Inc., (NASDAQ: CUE) an innovative immunotherapy company developing a novel, proprietary class of biologics engineered to.
- InvestorPlace•6 months ago
3 Stock Charts for Monday: Gap, CenterPoint Energy and Boston Scientific
Any doubters who got out of the stock market on Thursday -- or worse, shorted stocks in the midst of that weakness -- were blindsided on Friday. The S&P 500 jumped 3.43% on the last day of last week, bolstering the argument that the market is ready to recover. Apple (NASDAQ:AAPL) set the tone and the pace, bouncing back from Thursday's plunge with a 4.3% rebound. As it turns out, investors aren't quite so sure the company's in dire straits after all. Netflix (NASDAQ:NFLX) had the bigger and better day, however, advancing 9.7% after Goldman Sachs said the recent pullback was a buying opportunity. Losers were few and far between, though among the most noteworthy was Cue Biopharma (NASDAQ:CUE). Shares of the biotech stock tumbled 6.3%, though traders are still looking for a specific reason for the selling. So far, it can only be chalked up to volatility. InvestorPlace - Stock Market News, Stock Advice & Trading Tips While the big day on Friday certainly positions most stocks for more bullishness this week, the weekend and the sheer scope of the recent gains still poses the risk of profit-taking. Fortunately, stocks charts of Gap (NYSE:GPS), Boston Scientific (NYSE:BSX) and CenterPoint Energy (NYSE:CNP) look well positioned to move into trends regardless of what the broad market does, after several days of jockeying. ### Boston Scientific (BSX) In the middle of 2018, Boston Scientific looked unstoppable. Shares were not only in rally mode, they had broken past a major technical ceiling that had defined an uptrend that goes back to 2015. * 10 Oversold Stocks Due for a Bounce In retrospect though, that big run-up looks like it was only a setup for an even bigger corrective move. That's now well underway, but hardly complete yet. Click to Enlarge • BSX shares managed to pop back above the 200-day moving average line, plotted in white as of Friday, but one day doesn't bring the stock all the way back from that cliff's edge. • The most plausible downside target is a pullback to the same support line that's tagged all the major lowers going back to 2015. That level is currently at $29.00, but rising fast. • Any major bottom should also coincide with a stochastic indicator falling all the way below 20, and an RSI indicator that gets near there. That's the condition we saw take shape with past lows that led to recovery rallies. ### CenterPoint Energy (CNP) The 1.9% advance utility name CenterPoint Energy logged on Friday actually trailed the broad market's gain. But that gain is part of a much bigger breakout thrust effort that the broad market can't boast right now. It's unlikely we'll see a straight shot past the make-or-break technical ceiling ahead, but the slow bullish momentum is still well-established momentum. Click to Enlarge • The pivotal line is right around $29, plotted in blue on both stock charts. CenterPoint Energy shares have actually been above that mark since 2017, but not in a "normal" scenario. • It's evident on the daily chart, but more evident on the weekly chart that the $27/$29 span has been a trading range. The consolidation between those two lines has set the stage for a prolonged advance of $29 can be cleared. • Underscoring the bullish argument is the fact that CenterPoint is one of the few stocks with all key moving average lines sloped upward rather than downward. It's an indication of bullishness in multiple timeframes. ### Gap (GPS) Just because a stock loses ground on a day that the overall market moves higher doesn't inherently make that name un-ownable. On the other hand, any stock that isn't swept higher in a bullish charge likes Friday's can and should raise eyebrows. Gap is such a name, falling 1.6% on Friday and extending a well-established downtrend. Click to Enlarge • Friday's loss wasn't just an erroneous slide. It was a high-volume selloff that dragged Gap shares back under the falling 20-day moving average, which is one of several moving average lines that have steered the stock lower for months. • Notice that all the key moving average lines made bearish crosses between July and September. • Zooming out to a weekly chart we can see Friday's weakness is part of a well-defined downtrend that extends back to early last year. Since then, their divergences have widened. As of this writing, James Brumley did not hold a position in any of the aforementioned securities. You can follow him on Twitter, at @jbrumley. ### More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 7 Downtrodden Stocks to Fish From the Bottom * 8 Cheap Value Stocks That Just Got More Enticing * 5 Apple Suppliers Hurt by the Guidance Cut Compare Brokers The post 3 Stock Charts for Monday: Gap, CenterPoint Energy and Boston Scientific appeared first on InvestorPlace.
- GlobeNewswire•7 months ago
Cue Biopharma and LG Chem Life Sciences Announce WT1 as the Next Immuno-STAT™ Target in Oncology
Cue Biopharma™, Inc., (CUE) an innovative immunotherapy company developing a novel, proprietary class of biologics engineered to selectively modulate antigen-specific T cells to treat cancer, autoimmune and chronic infectious diseases, along with LG Chem Life Sciences, announced today the selection of Wilms’ Tumor 1 (WT1) as the target antigen for CUE-102, pursuant to the partners’ strategic research and development agreement.
- GlobeNewswire•8 months ago
Cue Biopharma Presents Foundational Data on Immuno-STAT Platform and CUE-101 at the Society for Immunotherapy of Cancer’s (SITC) 33rd Annual Meeting
Cue Biopharma™, Inc., (CUE) an innovative immunotherapy company developing a novel, proprietary class of biologics engineered to modulate antigen-specific T cells to treat cancer, autoimmune and chronic infectious diseases, announced today preclinical results demonstrating the potential of its Immuno-STAT™ (Selective Targeting and Alteration of T cells) platform and lead candidate CUE-101. The poster, entitled “CUE-101, a novel Fc fusion protein comprised of HLA-A*0201-bound HPV16 E7 peptide and IL-2, for selective targeting and expansion of anti-tumor T cells for treatment of HPV-driven malignancies,” (P185) is being presented today during the poster session at the Society for Immunotherapy of Cancer's (SITC) 33rd Annual Meeting being held in Washington, D.C.
- GlobeNewswire•8 months ago
Cue Biopharma Announces Strategic Collaboration with LG Chem Life Sciences for Immuno-STAT™ Biologics in Oncology
Collaboration Expands Development and Manufacturing of Immuno-STAT™ Biologics and Broadens Coverage of Patient Populations CAMBRIDGE, Mass., Nov. 08, 2018 -- Cue Biopharma™,.
- GlobeNewswire•9 months ago
Cue Biopharma Announces Presentation at the Society for Immunotherapy of Cancer’s (SITC) 33rd Annual Meeting
CAMBRIDGE, Mass., Oct. 30, 2018 -- Cue Biopharma™, Inc., (NASDAQ: CUE) an innovative immunotherapy company developing a novel, proprietary class of biologics engineered to.
- Simply Wall St.•9 months ago
What Kind Of Shareholders Own Cue Biopharma Inc (NASDAQ:CUE)?
The big shareholder groups in Cue Biopharma Inc (NASDAQ:CUE) have power over the company. Generally speaking, as a company grows, institutions will increase their ownership. Conversely, insiders often decrease their Read More...
